Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Vericel Corporation, Syndax Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Vericel Corporation, Syndax Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Vericel Corporation, Syndax Pharmaceuticals and Inc.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Latest Biotechnology and Vericel Corporation, Syndax Pharmaceuticals, Inc. Stock News

As of July 7, 2026, Vericel Corporation had a $2.4 billion market capitalization, compared to the Biotechnology median of $300.0 million. Vericel Corporation’s stock is NA in 2026, NA in the previous five trading days and up 12.48% in the past year.

Currently, Vericel Corporation’s price-earnings ratio is 111.3. Vericel Corporation’s trailing 12-month revenue is $292.1 million with a 7.3% net profit margin. Year-over-year quarterly sales growth most recently was 30.0%. Analysts expect adjusted earnings to reach $0.452 per share for the current fiscal year. Vericel Corporation does not currently pay a dividend.

Currently, Syndax Pharmaceuticals, Inc. does not have a price-earnings ratio. Syndax Pharmaceuticals, Inc.’s trailing 12-month revenue is $217.2 million with a -112.0% net profit margin. Year-over-year quarterly sales growth most recently was 224.5%. Analysts expect adjusted earnings to reach $-1.697 per share for the current fiscal year. Syndax Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Vericel Corporation, Syndax Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Vericel Corporation, Syndax Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Vericel Corporation, Syndax Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
Vericel Corporation	VCEL	A
Syndax Pharmaceuticals, Inc.	SNDX	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Vericel Corporation has a Growth Score of 89, which is Very Strong. Syndax Pharmaceuticals, Inc. has a Growth Score of 7, which is Very Weak.

The Growth Grade Winner: Vericel Corporation

As you can clearly see from the Growth Grade breakdown above, Vericel Corporation has a more attractive growth grade than Syndax Pharmaceuticals, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Vericel Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Vericel Corporation, Syndax Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Vericel Corporation	VCEL	A
Syndax Pharmaceuticals, Inc.	SNDX	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Vericel Corporation has a Quality Score of 82, which is Very Strong. Syndax Pharmaceuticals, Inc. has a Quality Score of 7, which is Very Weak.

The Quality Grade Winner: Vericel Corporation

As you can clearly see from the Quality Grade breakdown above, Vericel Corporation has a better overall quality grade than Syndax Pharmaceuticals, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Vericel Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Vericel Corporation, Syndax Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Vericel Corporation	VCEL	C
Syndax Pharmaceuticals, Inc.	SNDX	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Vericel Corporation has a Earnings Estimate Score of 56, which is Neutral. Syndax Pharmaceuticals, Inc. has a Earnings Estimate Score of 37, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Vericel Corporation, Syndax Pharmaceuticals or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Vericel Corporation, Syndax Pharmaceuticals or Inc. is the better investment when it comes to estimate revisions.

Other Vericel Corporation, Syndax Pharmaceuticals and Inc. Grades

In addition to Estimate Revisions, Growth and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Vericel Corporation, Syndax Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Vericel Corporation, Syndax Pharmaceuticals or Inc. Stock?

Overall, Vericel Corporation stock has a Growth Score of 89, Estimate Revisions Score of 56 and Quality Score of 82.

Syndax Pharmaceuticals, Inc. stock has a Growth Score of 7, Estimate Revisions Score of 37 and Quality Score of 7.

Comparing Vericel Corporation, Syndax Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.